Business
Enhertu DESTINY-PanTumor02 shows positive results
Enhertu DESTINY-PanTumor02 shows positive results.
About this update from Astrazeneca Plc
[{"type":"text","content":"\n \n \n 06 March 2023 07:00 GMT\n \n \n \n \n \n \n Enhertu\n \n \n showed clinically meaningful and durable responses across multiple HER2-expressing tumour types\n \n \n in DESTINY-PanTumor02 Phase II trial\n \n \n \n \n \n \n \n \n \n AstraZeneca and Daiichi Sankyo's Enhertu met prespecified criteria for objective response rate and duration of response\n \n \n \n \n \n \n \n \n Positive high-level results from an analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) met\n the prespecified target for objective response rate (ORR) and demonstrated durable response across multiple HER2-expressing advanced solid tumours\n in heavily pretreated patients.\n \n \n \n \n \n \n Enhertu\n \n is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo.\n \n \n \n \n \n The DESTINY-PanTumor02 Phase II trial is evaluating the efficacy and safety of Enhertu in patients with\n locally advanced, unresectable, or metastatic\n previously treated\n ,\n HER2-expressing solid tumours not eligible for curative therapy, including biliary tract, bladder, cervical, endometrial, ovarian, pancreatic, and rare cancers. The primary endpoint of the trial is investigator-assessed confirmed ORR and investigator-assessed duration of response (DoR) is a key secondary endpoint.\n \n \n \n \n \n The data will be presented at an upcoming medical meeting and shared with global regulatory authorities.\n \n \n \n \n \n HER2 is a tyrosine kinase receptor protein expressed on the surface of various tissue cells throughout the body and is involved in normal cell growth.1,2 In some cancer cells, HER2 expression is amplified or the cells have activating mutations.1,3 While HER2-directed therapies have been used to treat breast, gastric and lung cancers, more research is needed evaluating their potential role in treating other HER2-expressing tumour types.2,4-6\n \n \n \n \n \n Cristian Massacesi, Chief Medical Officer and Oncology Chief Development Officer, AstraZeneca, said, \"Enhertu has already demonstrated its potential to improve outcomes for patients with HER2-targetable breast, gastric and lung cancers, and these positive initial results in other tumo...